First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus

M. Rumpler, J. K. Mader, J. P. Fischer, R. Thar, J. M. Granger, F. Deliane, I. Klimant, F. Aberer, F. Sinner, T. R. Pieber, M. Hajnsek

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The combination of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion can be used to improve the treatment of patients with diabetes. The aim of this study was to advance an existing preclinical single-port system for clinical application by integrating the sensors of a phosphorescence based CGM system into a standard insulin infusion set. The extracorporeal optical phase fluorimeter was miniaturised and is now comparable with commercial CGM systems regarding size, weight and wear comfort. Sensor chemistry was adapted to improve the adhesion of the sensor elements on the insulin infusion set. In-vitro tests showed a linear correlation of R2=0.998 between sensor values and reference glucose values in the range of 0-300 mg/dl. Electrical and cytotoxicity tests showed no negative impact on human health. Two single-port devices were tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12 h. Without additional data processing, the overall median absolute relative difference (median ARD) was 22.5%. For some of the used devices the median ARD was even well below 10%. The present results show that individual glucose sensors performance of the single-port system is comparable with commercial CGM systems but further improvements are needed. The new system offers a high extent of safety and usability by combining insulin infusion and continuous glucose measurement in a single-port system which could become a central element in an artificial pancreas for an improved treatment of patients with type 1 diabetes mellitus.

Original languageEnglish
Pages (from-to)240-248
Number of pages9
JournalBiosensors & Bioelectronics
Volume88
DOIs
Publication statusPublished - 15 Feb 2017

Fingerprint

Medical problems
Type 1 Diabetes Mellitus
Glucose
Insulin
Equipment and Supplies
Monitoring
Sensors
Fluorometers
Glucose sensors
Artificial Pancreas
Phosphorescence
Subcutaneous Infusions
Cytotoxicity
Adhesion
Wear of materials
Health
Reference Values
Safety
Weights and Measures
Therapeutics

Keywords

  • Artificial pancreas
  • Continuous glucose monitoring
  • Optical glucose sensor
  • Phase fluorimeter
  • Single-port system
  • Type 1 diabetes mellitus

ASJC Scopus subject areas

  • Biotechnology
  • Biophysics
  • Biomedical Engineering
  • Electrochemistry

Cite this

First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus. / Rumpler, M.; Mader, J. K.; Fischer, J. P.; Thar, R.; Granger, J. M.; Deliane, F.; Klimant, I.; Aberer, F.; Sinner, F.; Pieber, T. R.; Hajnsek, M.

In: Biosensors & Bioelectronics, Vol. 88, 15.02.2017, p. 240-248.

Research output: Contribution to journalArticleResearchpeer-review

Rumpler, M, Mader, JK, Fischer, JP, Thar, R, Granger, JM, Deliane, F, Klimant, I, Aberer, F, Sinner, F, Pieber, TR & Hajnsek, M 2017, 'First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus' Biosensors & Bioelectronics, vol. 88, pp. 240-248. https://doi.org/10.1016/j.bios.2016.08.039
Rumpler, M. ; Mader, J. K. ; Fischer, J. P. ; Thar, R. ; Granger, J. M. ; Deliane, F. ; Klimant, I. ; Aberer, F. ; Sinner, F. ; Pieber, T. R. ; Hajnsek, M. / First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus. In: Biosensors & Bioelectronics. 2017 ; Vol. 88. pp. 240-248.
@article{3892d87b97dc413c8f05ac5d6252e484,
title = "First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus",
abstract = "The combination of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion can be used to improve the treatment of patients with diabetes. The aim of this study was to advance an existing preclinical single-port system for clinical application by integrating the sensors of a phosphorescence based CGM system into a standard insulin infusion set. The extracorporeal optical phase fluorimeter was miniaturised and is now comparable with commercial CGM systems regarding size, weight and wear comfort. Sensor chemistry was adapted to improve the adhesion of the sensor elements on the insulin infusion set. In-vitro tests showed a linear correlation of R2=0.998 between sensor values and reference glucose values in the range of 0-300 mg/dl. Electrical and cytotoxicity tests showed no negative impact on human health. Two single-port devices were tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12 h. Without additional data processing, the overall median absolute relative difference (median ARD) was 22.5{\%}. For some of the used devices the median ARD was even well below 10{\%}. The present results show that individual glucose sensors performance of the single-port system is comparable with commercial CGM systems but further improvements are needed. The new system offers a high extent of safety and usability by combining insulin infusion and continuous glucose measurement in a single-port system which could become a central element in an artificial pancreas for an improved treatment of patients with type 1 diabetes mellitus.",
keywords = "Artificial pancreas, Continuous glucose monitoring, Optical glucose sensor, Phase fluorimeter, Single-port system, Type 1 diabetes mellitus",
author = "M. Rumpler and Mader, {J. K.} and Fischer, {J. P.} and R. Thar and Granger, {J. M.} and F. Deliane and I. Klimant and F. Aberer and F. Sinner and Pieber, {T. R.} and M. Hajnsek",
year = "2017",
month = "2",
day = "15",
doi = "10.1016/j.bios.2016.08.039",
language = "English",
volume = "88",
pages = "240--248",
journal = "Biosensors & Bioelectronics",
issn = "0956-5663",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus

AU - Rumpler, M.

AU - Mader, J. K.

AU - Fischer, J. P.

AU - Thar, R.

AU - Granger, J. M.

AU - Deliane, F.

AU - Klimant, I.

AU - Aberer, F.

AU - Sinner, F.

AU - Pieber, T. R.

AU - Hajnsek, M.

PY - 2017/2/15

Y1 - 2017/2/15

N2 - The combination of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion can be used to improve the treatment of patients with diabetes. The aim of this study was to advance an existing preclinical single-port system for clinical application by integrating the sensors of a phosphorescence based CGM system into a standard insulin infusion set. The extracorporeal optical phase fluorimeter was miniaturised and is now comparable with commercial CGM systems regarding size, weight and wear comfort. Sensor chemistry was adapted to improve the adhesion of the sensor elements on the insulin infusion set. In-vitro tests showed a linear correlation of R2=0.998 between sensor values and reference glucose values in the range of 0-300 mg/dl. Electrical and cytotoxicity tests showed no negative impact on human health. Two single-port devices were tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12 h. Without additional data processing, the overall median absolute relative difference (median ARD) was 22.5%. For some of the used devices the median ARD was even well below 10%. The present results show that individual glucose sensors performance of the single-port system is comparable with commercial CGM systems but further improvements are needed. The new system offers a high extent of safety and usability by combining insulin infusion and continuous glucose measurement in a single-port system which could become a central element in an artificial pancreas for an improved treatment of patients with type 1 diabetes mellitus.

AB - The combination of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion can be used to improve the treatment of patients with diabetes. The aim of this study was to advance an existing preclinical single-port system for clinical application by integrating the sensors of a phosphorescence based CGM system into a standard insulin infusion set. The extracorporeal optical phase fluorimeter was miniaturised and is now comparable with commercial CGM systems regarding size, weight and wear comfort. Sensor chemistry was adapted to improve the adhesion of the sensor elements on the insulin infusion set. In-vitro tests showed a linear correlation of R2=0.998 between sensor values and reference glucose values in the range of 0-300 mg/dl. Electrical and cytotoxicity tests showed no negative impact on human health. Two single-port devices were tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12 h. Without additional data processing, the overall median absolute relative difference (median ARD) was 22.5%. For some of the used devices the median ARD was even well below 10%. The present results show that individual glucose sensors performance of the single-port system is comparable with commercial CGM systems but further improvements are needed. The new system offers a high extent of safety and usability by combining insulin infusion and continuous glucose measurement in a single-port system which could become a central element in an artificial pancreas for an improved treatment of patients with type 1 diabetes mellitus.

KW - Artificial pancreas

KW - Continuous glucose monitoring

KW - Optical glucose sensor

KW - Phase fluorimeter

KW - Single-port system

KW - Type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84994533191&partnerID=8YFLogxK

U2 - 10.1016/j.bios.2016.08.039

DO - 10.1016/j.bios.2016.08.039

M3 - Article

VL - 88

SP - 240

EP - 248

JO - Biosensors & Bioelectronics

JF - Biosensors & Bioelectronics

SN - 0956-5663

ER -